Susan Bobulsky Sells 487 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $22.00, for a total value of $10,714.00. Following the completion of the sale, the insider owned 406,288 shares of the company’s stock, valued at $8,938,336. The trade was a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $19.00, for a total transaction of $95,000.00.
• On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total transaction of $198,000.00.

Adaptive Biotechnologies Stock Performance

Shares of Adaptive Biotechnologies stock opened at $20.82 on Wednesday. The stock’s fifty day moving average is $16.38 and its 200 day moving average is $15.94. Adaptive Biotechnologies Corporation has a one year low of $9.96 and a one year high of $22.80. The stock has a market cap of $3.33 billion, a P/E ratio of -63.09 and a beta of 2.07.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.20) earnings per share. Analysts predict that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Institutional Trading of Adaptive Biotechnologies

A number of large investors have recently made changes to their positions in ADPT. California State Teachers Retirement System raised its position in Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after purchasing an additional 933 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Adaptive Biotechnologies by 6.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock worth $205,000 after buying an additional 941 shares in the last quarter. Captrust Financial Advisors increased its stake in shares of Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after buying an additional 1,119 shares during the period. Assetmark Inc. raised its holdings in shares of Adaptive Biotechnologies by 46.4% in the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after acquiring an additional 1,401 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Adaptive Biotechnologies by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after acquiring an additional 1,532 shares in the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ADPT has been the topic of a number of research reports. Guggenheim lifted their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, June 29th. JPMorgan Chase & Co. reduced their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. TD Cowen boosted their target price on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Morgan Stanley dropped their price target on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $20.50.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.